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Abstract
Background: Dzherelo (Immunoxel) is one of the few approved immunomodulators that has been shown to
produce positive treatment outcomes in patients with tuberculosis (TB). The aim of this review was to assess the
effectiveness of Immunoxel used as adjunct therapy with conventional anti-TB therapy for the treatment of
pulmonary TB.
Methods: Comprehensive search was conducted in different major databases: PubMed (MEDLINE), EMBASE (OVID),
Cochrane Central Register of Controlled Trials (CENTRAL), Scopus (Elsevier). We also searched Google Scholar along
with trial registries and hand-searched the reference list of identified original research as well as review articles.
Conference proceedings of relevant TB and lung disease annual conferences were also screened. Two independent
authors extracted outcome data using a standardised extraction form. Relative risk (RR), mean difference (MD) and
standardised mean difference (SMD) with a 95% confidence interval (CI) were used as measures of effect. We
assessed certainty of evidence using GRADE.
Results: Six clinical trials, which met the criteria for the review, were identified, and these provided data for the
review. Overall results from the six trials that compared antituberculosis treatment (ATT) alone versus ATT and
Immunoxel, and ATT and placebo versus ATT and Immunoxel showed an increased number of patients becoming
sputum-negative in the Immunoxel group (RR 3.19; 95% CI 2.44 to 4.17; 488 participants). There was also reduction
in body temperature among patients receiving Immunoxel compared to ATT alone (MD −0.20, 95% CI −0.22 to
−0.18, 345 participants). However, there were no differences in body weight changes across all the studies (MD
5.65; 95% CI −0.80 to 12.11; 382 participants).
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Conclusion: Current evidence indicates that the use of Immunoxel as an adjunctive treatment in patients with
pulmonary tuberculosis has the potential to enhance the efficacy of antituberculosis treatment. However, well-
designed, conducted and adequately powered clinical trials are needed to establish the effectiveness of this
adjunctive treatment.
Systematic review registration: PROSPERO registration number: CRD42019127823
Keywords: Immunoxel, Dzherelo, Tuberculosis, Antituberculosis treatment (ATT), Adjunctive therapy, Meta-analysis,
Clinical trials, Immunotherapy
Background
Tuberculosis (TB) has existed for millennia and remains
one of the major public health concerns [1]. In 2019, 1.4
million deaths that are due to TB were recorded includ-
ing an estimated 10 million new incident cases world-
wide [1]. Drug-resistant TB continues to be a threat to
TB management despite the fact that, with a timely diag-
nosis and appropriate treatment, most of the people who
contract TB could be cured [1]. The standard treatment
regimens for latent TB infection take 3–9 months, and
new incident cases of TB require at least 6 months of
treatment with multiple drugs [2]. A decline in the suc-
cess rate of treatment and the increase in multidrug-
resistant TB or rifampicin-resistant TB (MDR/RR-TB)
indicate the urgent need for better treatment options [1,
2]. One of the interventions that could be employed in
addressing these challenges is immunotherapy. This is
believed to enhance the efficacy of TB chemotherapy
and to potentially shorten the treatment duration [3].
Dzherelo (Immunoxel) is an oral immunomodulatory
botanical compound that strengthens the immune sys-
tem and aids the ability of the host to clear infectious
diseases by restoring humoral and cellular immunity and
increasing interferon production [3]. Immunoxel is one
of the few approved immunomodulators that has been
shown to produce positive outcomes in patients with
TB. Immunoxel was formulated in 1980 by a Ukrainian
scientist Volodymyr Pylypchuk (Ekomed company) and
is currently widely available in Ukraine as an oral immu-
nomodulating agent [4]. The Ministry of Health in
Ukraine approved the formulation of Immunoxel in
1997 as a dietary herbal supplement following compre-
hensive laboratory and clinical testing [5]. In 2016,
Immunoxel was officially approved as an oral immuno-
modulator by the Ukrainian Ministry of Health.
Many clinical studies involving patients with or with-
out HIV/TB co-infection were carried out in Ukraine to
assess the effectiveness of Immunoxel [5–7]. Approxi-
mately 90% of patients included in these studies reported
objective improvement in their well-being, as demon-
strated by an increase in body weight, improved liver
function, and decrease in incidence of opportunistic in-
fections [8]. Moreover, by the 6th month of follow-up,
the proportion of cured TB patients by culture and radi-
ology was about 2–4 folds higher than of those who re-
ceived standard first-line antituberculosis treatment
(ATT) alone [5].
Immunoxel can also eliminate Mycobacterium tubercu-
losis, and this is proved by accelerating sputum conver-
sion; improving chest image, especially cavity closure; and
improved overall respiratory function as well as clinical
features such as reversal of weight loss, correction of the
hepatotoxicity caused by TB drugs and increase in the ab-
solute number of CD4 and CD8 T-lymphocytes [6]. In
addition, the use of this immunomodulator alongside with
ATT has been proven to shorten the duration of treat-
ment as compared to using standard ATT alone [6]. Al-
though several clinical trials have been conducted to date,
this evidence has not yet been assessed in a systematic re-
view. We therefore conducted a systematic review of the
current existing evidence to assess effectiveness of adjunct
Immunoxel with conventional anti-TB therapy for the
treatment of pulmonary tuberculosis.
Materials and methods
The methods of this systematic review and meta-analysis
were reported as per the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols (PRIS
MA-P) checklist. We registered the protocol for this sys-
tematic review on the International Prospective Register
of Systematic Reviews (PROSPERO) with a registration
number: CRD42019127823.
Types of studies
We included randomised and non-randomised con-
trolled trials (RCT and non-RCT) that evaluated the ad-
junct effects of Immunoxel in TB patients allocated to
adjunct Immunoxel with standard-of-care anti-TB treat-
ment (standard TB treatment) and standard TB treat-
ment with placebo or standard TB treatment alone.
Types of participants
We included pulmonary TB patients older than 18 years,
irrespective of resistance types.
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Types of interventions
 Intervention group: adjunct Immunoxel with
standard-of-care anti-TB treatment (standard TB
treatment)
 Comparison group: standard TB treatment with
placebo or standard TB treatment alone.
We did not impose any restrictions on study interven-
tions, such as dose, timing of outcomes measurement
and duration of treatment.
Types of outcomes measures
Primary outcome
The primary outcome for this review was sputum smear
conversion. This is defined as the proportion of patients
with sputum that has been converted to negative at a
certain point in time after initiation of anti-TB treatment
and are therefore no longer infectious.
Secondary outcome
Safety We defined safety as the occurrence, after initi-
ation of the study drug treatment, of either:
 An increase in body weight from baseline (P<0.05)
by the end of study.
 A decrease in levels of alanine transaminase and
total bilirubin from baseline (P<0.05) by the end of
the study.
Electronic searches
A comprehensive and exhaustive search was performed
by MKK, one of the three review authors, with the help
of an information specialist to identify relevant studies
in the following electronic databases: PubMed (MEDL
INE), EMBASE (OVID), Cochrane Central register of
controlled trials (CENTRAL), Scopus (Elsevier). We
searched Google Scholar and also looked for ongoing
RCTs of adjunctive therapies in TB in the following
registries:
 US National Institute of Health Ongoing Trials
Register (www.clinicaltrials.gov)
 World Health Organization International Clinical
Trials Register Platform (WHO ICTRP) (www.who.
int/ictrp)
 Pan African Clinical Trials Registry (PACTR) (www.
pactr.samrc.ac.za)
Searches were run on 21 May 2020 and were not re-
stricted to date, language, or publication status. Detailed
search strategies are presented in Additional file 1.
Searching other resources
We also hand-searched the reference list of included
studies. Conference proceedings of the International
Union against Tuberculosis and Lung Disease (IUATLD)
World Congress, The European Respiratory Society
World Congress Conferences and the American Thor-
acic Society International Congress were screened in
order to retrieve information on any further trials that
may not have been included in the electronic database.
Study selection
Search results were imported into Covidence (Covidence
Systematic Review Software, Veritas Health Innovation,
Melbourne, Australia), and three review authors (MKK,
BP and SM) independently screened the titles and ab-
stracts obtained from the electronic searches, as well as
full texts of all potentially eligible studies using a standar-
dised eligibility form with predefined inclusion criteria.
Disagreement between the authors who assessed study eli-
gibility was resolved by discussion and consensus.
Data extraction and management
Two review authors (MKK and BP) independently ex-
tracted data from included studies using a standardised
data extraction form and performed risk of bias
assessment. Extracted information included details of
the study, participants, interventions and outcomes.
Moreover, we assessed the risk of bias for RCTs using
the Cochrane risk of bias for randomised controlled tri-
als as described in the Cochrane Handbook for System-
atic Reviews of Interventions [9]. Thus, the assessment
of risk of bias took into account the variation in the
study designs (RCTs and non-RCTs), as certain criteria
were only applicable to RCTs and others were only ap-
plicable to non-randomised studies.
Disagreement between authors who extracted the data
and assessed the risk of bias was resolved by discussion
and consensus. We planned to assess for publication bias
using funnel plot, but this was not done due the insuffi-
cient number of studies included in this review. Data
were entered into the Review Manager 5.4 statistical
Software [10].
Statistical analysis
Dichotomous data were presented and compared using
risk ratio while continuous outcomes were presented
and compared using mean difference (MD). Further-
more, as studies used different units to measure some of
the biochemical parameters, standardised mean differ-
ence (SMD) was used to present and compare data, we
assumed SMD of 0.2 to represent a small effect, 0.5 a
medium effect and 0.8 a large effect accordingly [11]. All
measures of effect were reported with their correspond-
ing 95% confidence intervals (CI).
Kitenge et al. Systematic Reviews          (2021) 10:157 Page 3 of 11
We assessed heterogeneity between trial results by visu-
ally inspecting the forest plots for overlapping confidence
intervals, followed by the chi-squared test of homogeneity
(with significance defined at an alpha of 10%). We then
used the I2 test to quantify the degree of heterogeneity.
We conducted meta-analysis when included studies were
similar in terms of interventions, participants, and out-
comes. We pooled the results using the Mantel-Haenszel
method and fixed model effects. When there was substan-
tial heterogeneity, we used random-effects model. When
I2 was greater than 50%, we considered it to be substantial
heterogeneity and explored the cause of heterogeneity
using subgroup analyses. All the analyses were performed
using RevMan 5.4.
Finally, GRADE approach [12–14] was used to assess
the quality of evidence for the adjunct effect of Immu-
noxel. We recorded the quality of evidence as high,
moderate, low or very low.
Results
Study flow chart and description of studies
Results of study selection processes are described in a
flow diagram (Fig. 1). We identified 25 records through
a comprehensive and exhaustive search. Twenty-five
titles and abstracts were screened, and 10 articles were
deemed to be irrelevant. Following the full-text
assessment, independent review and discussion, of the
remaining 15 full text articles, we included 6 studies
[5–8, 15, 16]. We have provided reasons for excluding
irrelevant studies in Table 1.
Excluded studies
Zulkifli et al. [17] and Prihoda et al. [21] were excluded
because they were not clinical trials. Butov and col-
leagues [18] were excluded because the intervention
used is not under this review. Nikolaeva et al. [19, 20]
was excluded because their study did not report any of
the study outcomes in this review. Studies [4, 8, 23] were
excluded after finding out that they were duplicate stud-
ies and therefore were results of a publication bias (stud-
ies published in two different journals using different
titles). Furthermore, Prihoda et al. [22] was excluded be-
cause the study used Immunoxel combined with other
forms of immunotherapies. The details for exclusion of
studies are provided in Table 1.
Included studies
We provided detailed information of the included stud-
ies and summarise key features (Table 2). All studies
were conducted in Ukraine, including one multicentre
conducted in Ukraine and Mongolia [5]. Two studies
were open-label RCT, one double-blinded placebo RCT,
one unblinded RCT and one clinical trial with unspeci-
fied methods. Batbold et al. [5] was the most powered of
Fig. 1 Flow chart for studies in the review
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the studies included in this review (269 participants).
Zaitzeva et al. enrolled 75 newly diagnosed TB patients
[8]. Efremenko et al. randomly allocated 69 participants
to one of the four different types of Immunoxel formula-
tions [7]. Furthermore, Zaitzeva et al. matched 66 partic-
ipants to receive either individualised ATT or ATT with
liquid Immunoxel [16]; and Arjanova et al. matched 40
participants to receive either ATT or ATT with
Immunoxel [15]. The study population for five trials
were in-patients; however, one trial did not clearly spe-
cify its study population as to whether they were inpa-
tients or outpatients.
Four studies compared liquid-based formulation, 50
drops of Immunoxel twice daily, with placebo [6, 8, 15,
16]. One study compared four different formulations of
Immunoxel given once per day [7], and one study com-
pared unspecified Immunoxel to placebo [5].
Risk of bias
A graphical representation of the overall risk of bias in
the included studies is presented in Figs. 2 and 3. All tri-
als had a higher risk of bias due to unreported, inad-
equate or unclear methods of random sequence
generation and lack of allocation concealment. Three
studies [6, 7, 15, 16] did not report how the allocation
was generated. Batbold et al. [5] used a computer to gen-
erate the allocation while Zaitzeva et al. [8] did not allo-
cate groups randomly. All the studies did not report
how the allocations were concealed.
Concerning blinding, Arjanova et al. [15] did not state
the exact method used. Batbold et al. [5] reported that
neither study personnel nor patients were aware of the
intervention. Efremenko et al. [7] reported that only out-
come assessors were blinded. Moreover, Zaitzeva et al.
did not report the exact method used for blinding [16]
and finally Zaitzeva et al. [8] was an open label.
Selective reporting was difficult to assess, considering
the fact that none of the studies reported a protocol be-
ing available. Nevertheless, primary endpoints were
Table 1 Characteristics of excluded studies
Study Reason for exclusion
Amin [4] This was a review [4]
Zulkifli et al.
[17]
Study was a systematic review [17]
Butov et al.
[18]








This study [20] was duplicate of study [19]
Nikolaeva et al.
[19]
The study did not report any of the outcomes of
interest, the study looked particularly at the effect of
Dzherelo on immunological and virological responses




Not a comparative study, in addition, all the
participants received the intervention in combination
with some other immunomodulators [21].
Prihoda et al.
[22]
The study compared Dzherelo (Immunoxel) with other
forms of immunotherapies (Svitanok and Lizorm) [22].
Prihoda et al.
[23]
This study [23] was a duplicate of study [21].
Table 2 Characteristics of included studies
Trials Country Study
design




























69 patients, 76.8% with TB and 23.2% with TB/HIV
co-infection
Various Immunoxel formulations:
sugar dragees, sugar-coated pills,












75 newly PTB patients to assess the adjunct effect
of Dzherelo on clinical outcomes and biochemical
and blood parameters in patients with cavitary and
infiltrating PTB







66 patients of which 48 had MDR-TB Immunoxel with ATT ATT alone [16]
ATT antituberculosis therapy, RCT randomised controlled trial
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reported as specified in the study objectives. Arjanova
et al. [15] as well as Efremenko et al. [7] provided very
limited information relative to the methods.
Effect of interventions on smear conversion
Five trials including 488 participants contributed to this
outcome [5–8, 15]. There was evidence of an increased
number of patients becoming sputum-negative in the
Immunoxel group (RR 3.19; 95% CI 2.44 to 4.17) (Fig. 4).
Heterogeneity was not important among these studies
(Chi2=4.04, degree of freedom (DF) =4 (P<0.40); I2=1%)
(Fig. 3). The quality of this evidence was low.
Effect of interventions on weight change
There were two studies that compared ATT alone with
ATT plus Immunoxel [5, 7, 15] and one study that com-
pared ATT alone with ATT plus multiple formulations
of Immunoxel [6]. Pooled analysis of data provided by 3
studies with 382 participants showed that there was no
evidence of a difference in weight change (MD 5.65, 95%
CI −0.80 to 12.11). There was a substantial statistical
heterogeneity (Tau2= 32.11; Chi2=212.98, degree of free-
dom (DF=2) P<0.00001; I2=99%) (Fig. 5) and marked
clinical heterogeneity between studies contributing to
the outcomes. The quality of this evidence was very low.
We also conducted subgroup analysis for this outcome
to investigate heterogeneity. This subgroup analysis eval-
uated ATT alone versus ATT plus placebo; only one
study compared Immunoxel to ATT alone (MD 14.30,
95% CI 12.59 to 19.01) [15]. When analysis of this study
was separated from the remaining of the studies, the
pooled weight change continues to show an increase
among participants who received Immunoxel compared
to placebo, and studies included in the analysis were
relatively homogenous (MD 1.40, 95% CI 1.11 to 1.69)
Fig. 2 Risk of bias summary: review authors’ judgement about each
risk of bias item for each included study
Fig. 3 Risk of bias graph: review authors’ judgement about each risk of bias item presented as percentages across all included studies
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(Chi2=25.62, degree of freedom (DF)=1 (P<0.00001); I2=
0%). The test for subgroup differences indicated that
there is statistically significant subgroup effect (P<
0.00001).
Effect of interventions on level of alanine transaminase
Three studies including 410 participants contributed to
this outcome [5, 8, 16]. There was a large reduction in
level of alanine transaminase (ALAT) among partici-
pants receiving Immunoxel compared to ATT alone
(SMD −17.90, 95% CI −32.20 to −3.59). There was a
substantial statistical heterogeneity among these studies
(Chi2=169.89, degree of freedom (DF) =2, P<0.00001; I2=
99%) (Fig. 6), and the quality of evidence was very low.
A SMD was used to determine the effect of Immunoxel
as included studies used different units to measure ala-
nine transaminase. We also conducted subgroup analysis
for this outcome to investigate heterogeneity. This sub-
group analysis evaluated ATT alone versus ATT plus
placebo. There was only one study that compared ATT
plus placebo with ATT plus Immunoxel (SMD −4.32,
95% CI −4.76 to −3.88) [5]. When analysis of this study
was separated from the remaining of the studies, the
pooled ALAT showed larger change among participants
who received Immunoxel compared to placebo and con-
siderable heterogeneity persisted in the analysis (SMD
Fig. 4 Effect of Immunoxel compared with ATT alone or ATT with placebo on smear microscopy conversion
Fig. 5 Effect of Immunoxel compared with ATT alone or ATT with placebo on weight change
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−24.87, 95% CI −40.66 to −9.07) (Chi2=25.62, degree of
freedom (DF) =1 (P<0.00001); I2=96%).
Effect of intervention on total bilirubin
Two studies evaluated effect of Immunoxel on total bili-
rubin. The total number of participants in the Immu-
noxel and control group was 165 and 160, respectively
[5, 8]. There was no evidence of bilirubin reduction
among participants receiving Immunoxel compared to
control (SMD −5.82, 95% CI −14.99 to 3.35). There was
a substantial heterogeneity (Tau2 =43.80; Chi2=25545.12,
degree of freedom (DF=1), P<0.00001; I2=100%) (Fig. 7),
and marked clinical heterogeneity between studies con-
tributing to the outcomes and the quality of this evi-
dence was very low.
Effect of intervention on body temperature
Two trials including 345 participants contributed to this
outcome [5, 7]. There was evidence of a decreased body
temperature among participants in the Immunoxel
group (MD −0.20; 95% CI −0.22 to −0.18); homogeneity
was not important (Chi2=0.00, degree of freedom (DF) =
1 (P=1.0); I2=0%) (Fig. 8); the quality of this evidence
was low.
Discussion
Our systematic review and meta-analysis aimed to assess
the effectiveness of adjunctive Immunoxel therapy for
the treatment of pulmonary TB. We found six studies
with a total of 563 participants, which addressed five
outcomes. There was an overall positive effect of Immu-
noxel in sputum smear conversion; however, studies
contributing to this outcome were small and of poor
quality (low quality of evidence). Therefore, poor quality
of evidence precludes drawing firm conclusions regard-
ing the effect of the Immunoxel as an adjunctive
immunotherapy.
Previous investigations also showed that Immunoxel
resulted in a higher rate of clearance of M. tuberculosis
in sputum cultures than in patients treated with TB drug
alone or with placebo [6, 23]. Immunoxel eliminates
Mycobacterium tuberculosis by accelerating sputum con-
version, improving chest image especially cavity closure
and also improving overall clinical features and respira-
tory functions [15, 20]. These positive results are related
with better immune response as Immunoxel could regu-
late both humoral and cellular immune response [20].
Immunoxel plays important roles in the following: (i)
higher IL-2 and IFN- which have a role in accelerated
mycobacterium elimination, (ii) suppressed IL-2 which
Fig. 6 Effect of Immunoxel compared with ATT alone or ATT with placebo on level of alanine transaminase
Fig. 7 Effect of Immunoxel compared with ATT alone or ATT with placebo on total bilirubin
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interrupt cellular immune response, (iii) lower TNF-α.
The lower TNF-α is usually related with worse result. It
was shown that Immunoxel can efficiently reduce pro-
inflammatory cytokines [24]; thus, immunotherapies
should be aimed at downregulation rather than exacer-
bating an already intense immune response. However, it
is unclear how the downregulation of inflammation cor-
relates with bacterial clearance. The mechanism of ac-
tion of Immunoxel is unknown, and further studies
addressing this question needs to be carried out.
Notably, the remarkable effect of Immunoxel reported
across studies is body weight gain, but our review did
not find a significant difference in body weight gained.
However, an improved liver function and decrease in
body temperature were noted. A major limitation of the
current review in support of Immunoxel is the small
number of the included studies. Small trials can provide
firm and definitive answers to questions regarding safety
of therapy when outcomes are dichotomous [25]. How-
ever, the findings of small trials are misleading due to
random error [26]. Moore et al. demonstrated that for
the results to be statistically significant and clinically
meaningful, 500 participants per comparison group are
needed, which can be achieved by conducting a large
trial or by pooling results from multiple studies of small
size [27]. We understand the rather unusual path that
Immunoxel has made on its way to testing in phase 3
studies as literature on preclinical experimental data,
toxicity and dose finding is still unknown.
A further challenge in this review is the high degree of
heterogeneity observed in the outcomes reported across
studies. With an exception of the effect of Immunoxel
on smear conversion and body temperature, the
remaining outcomes varied widely across the different
studies. Another challenge in this review is that the in-
cluded studies were all conducted in Ukraine, with the
exception of one study [5], conducted in both Ukraine
and Mongolia, but that also was initiated by the same
Ukrainian co-authorship team. This may affect the pro-
jections of the inferences from the review to other low-
and middle-income settings.
It is unlikely that we missed any relevant RCTs and
non-RCT that could have assessed the clinical benefit of
Immunoxel used as adjunct with conventional anti-TB
therapy for the treatment of pulmonary TB. Apart from
the electronic and manual searches, Immunoxel manu-
facturers were contacted but unfortunately, we could not
obtain any information about studies of Immunoxel
from the manufacturer. The current review highlights
inappropriate reporting of trials by authors, which makes
judgement of the quality of the studies challenging.
CONSORT guidelines were established for reporting tri-
als; however, it is not always possible in a practical set-
ting to follow all the CONSORT guidelines.
We were unable to formally assess the likelihood of
publication bias in this review due to small number of
studies included per criterion. However, as publication
bias is more likely with small trials, this could be an al-
ternative explanation of the positive findings seen in the
studies we identified [28].
Quality of evidence
We used the GRADE approach to assess the certainty of
evidence as shown in the summary of findings table in
Additional file 2. The overall quality of evidence in this
review on the use of Immunoxel as adjunctive treatment
in patient with pulmonary tuberculosis is low due to
high risk of bias. Additionally, we also observed substan-
tial heterogeneity in included studies. Based on the
above quality of evidence, the implication is that there is
need for further research particularly involving RCT de-
sign in order to enhance our quality of evidence.
Implications for practice and future research
The current evidence suggests the use of Immunoxel as
adjunctive treatment in patients with pulmonary tuber-
culosis. However, the paucity of data encountered sug-
gests that there is room for more rigorous and carefully
designed clinical trials to confirm these findings. Since
RCT are the gold standard for testing the effect of new
treatment, it would be useful to see adequately powered
trials to establish the value of Immunoxel as adjunctive
Fig. 8 Effect of Immunoxel compared with ATT alone or ATT with placebo on body temperature
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treatment in patients with pulmonary tuberculosis and
increase the certainty of the current evidence base, pref-
erably in placebo-controlled settings. Careful attention
should be given to the outcomes to be assessed in future
trials to ensure that selected outcomes are important to
patients and are measured in a standardised manner and
longer duration.
Conclusion
The findings of this systematic review indicate that the
use Immunoxel as adjunctive treatment in patients with
pulmonary tuberculosis has the potential to enhance the
efficacy of the antituberculosis treatment. However, in
order to draw a firm conclusion, methodologically rigor-
ous and well-reported trials are required to confirm
these findings. The results of this systematic review also
lay an important foundation on which further studies
could be built on.
Abbreviations
ALAT: Alanine transaminase; ATT: Antituberculosis treatment;
CONSORT: Consolidated Standard of Reporting Trials; DF: Degree of freedom;
GRADE: Grading of Recommendations, Assessment, Development and
Evaluations; HIV: Human immunodeficiency virus; IUATLD: International
Union Against Tuberculosis and Lung Disease; MD: Mean difference; MDR-
TB: Multidrug-resistant tuberculosis; PRISMA-P: Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols; PROSPERO: Prospective
Register of Systematic Reviews; RCT: Randomised controlled trials;
RR: Relative risk; SMD: Standardised mean difference; TB: Tuberculosis
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13643-021-01698-2.
Additional file 1. Search strategies.
Additional file 2. Summary of findings table.




MK, BP, SP and PN contributed to the conceptualization of the project. MK,
BP, SP, MO and PN designed the search strategy, study selection process and
drafting of the manuscript. MK, BP, SP, MO and PN contributed to critically
reviewing the manuscript. All the authors gave the final approval of the
manuscript for publication. PN is the guarantor.
Funding
No funding was received for this systematic review
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its additional files.
Declarations
Ethics approval and consent to participate




The authors declare that they have no competing interests.
Author details
1Division of Epidemiology and Biostatistics, Department of Global Health,
Faculty of Medicine and Health Sciences, Stellenbosch University, Cape
Town, South Africa. 2Medecins sans Frontieres, Doctors without Borders,
Eshowe Project, Eshowe, KwaZulu Natal, South Africa. 3Clinical Services
Ministry of Health, P.O Box 30377, Lilongwe 3, Malawi. 4National Health
Laboratory Services, Dr George Mukhari Hospital/Sefako Makgatho Health
Sciences University, Pretoria, South Africa. 5Department of Pharmacology,
Sefako Makgatho Health Sciences University, Pretoria, South Africa. 6Division
of Epidemiology and Biostatistics, School of Public Health, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Received: 27 November 2020 Accepted: 10 May 2021
References
1. World Health Organization. Global tuberculosis report 2020. Geneva: World
Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available at
https://www.who.int/publications/i/item/9789240013131.
2. Zumla A, Chakaya J, Centis R, Ambrosio LD, Mwaba P, Bates M, et al.
Tuberculosis treatment and management — an update on treatment
regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;
3(3):220–34. https://doi.org/10.1016/S2213-2600(15)00063-6.
3. Abate G, Hoft D. Immunotherapy for tuberculosis: future prospects.
Immunotargets Ther. 2016;5:37–45. https://doi.org/10.2147/ITT.S81892.
4. Zulkifli Amin SPH. Promising herbals as adjunctive to standard
antituberculosis therapy. Indian J Public Health. 2020;11(1):1–8.
5. Batbold U, Butov DO, Kutsyna GA, Damdinpurev N, Grinishina EA, Mijiddorj
O, et al. Double-blind, placebo-controlled, 1:1 randomized phase III clinical
trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269
patients with pulmonary tuberculosis. Immunotherapy. 2017;9(1):13–24.
https://doi.org/10.2217/imt-2016-0079.
6. Arjanova OV, Prihoda ND, Yurchenko LV. Impact of adjunct immunotherapy
with multi-herbal supplement Dzherelo (Immunoxel) on treatment
outcomes in end-stage TB/HIV patients. J Antivirals. 2010;1(2):86–8.
7. Efremenko YV, Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI,
Mospan IV, et al. Clinical validation of sublingual formulations of Immunoxel
(Dzherelo) as an adjuvant immunotherapy in treatment of TB patients.
Immunotherapy. 2012;4(3):273–82. https://doi.org/10.2217/imt.11.176.
8. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk
VS, et al. Treatment of cavitary and infiltrating pulmonary tuberculosis with
and without the immunomodulator Dzherelo. Clin Microbiol Infect. 2009;
15(12):1154–62. https://doi.org/10.1111/j.1469-0691.2009.02760.x.
9. Green S, Higgins JPT, Alderson P, Clarke M, Mulrow CD, Oxman AD. Chapter
1: Introduction. In: Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions. Chichester: Wiley; 2008. https://doi.
org/10.1002/9780470712184.ch1.
10. RevMan. The Nordic Cochrane Centre, the Cochrane collaboration. Review
Manager (RevMan). Version 5.3 Copenhagen. 2014.
11. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed.
Hillsdale: L. Erlbaum Associates; 1988. p. 567.
12. Dijkers M. Introducing GRADE: a systematic approach to rating evidence in
systematic reviews and to guideline development. KT Update. Austin, TX:
SEDL, Center on Knowledge Translation for Disability and Rehabilitation
Research. 2013;(1)5.
13. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading
quality of evidence and strength of recommendations. BMJ. 2004;328(7454):
1490. https://doi.org/10.1136/bmj.328.7454.1490.
14. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE
guidelines: 1. Introduction - GRADE evidence profiles and summary of
findings tables. J Clin Epidemiol. 2011;64(4):383–94. https://doi.org/10.1016/j.
jclinepi.2010.04.026.
15. Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Vihrova LA,
Pylypchuk VS, et al. Enhancement of efficacy of tuberculosis drugs with
Immunoxel (DzhereloTM) in HIV-infected patients with active pulmonary
tuberculosis. Immunotherapy. 2009;1(4):549–56. https://doi.org/10.2217/imt.
09.25.
Kitenge et al. Systematic Reviews          (2021) 10:157 Page 10 of 11
16. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk
VS, et al. Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in
treatment of patients with multi-drug resistant TB (MDR-TB) in comparison
to standard chemotherapy. Res J Med Sci. 2009;3:36–41.
17. Zulkifli A, Purnama H.S. Promising herbals as adjunctive to standard
antituberculosis therapy. Indian J Public Heal Res Dev. 2017; 8 (2):220-225
18. Butov DA, Efremenko YV, Prihoda ND, Yurchenko LI, Sokolenko NI, Arjanova
OV, et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB,
treatment-failed TB, multidrug-resistant TB and TB/HIV. Futur Med. 2012:
687–95.
19. Nikolaeva LG, Maystat TV, Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna
GA. Changes in CD4+ T-cells and HIV RNA resulting from combination of
anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des
Devel Ther. 2009;2:87–93.
20. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YL, Masyuk LA, Kutsyna
GA. Effect of oral immunomodulator Dzherelo in TB/HIV co-infected
patients receiving anti-tuberculosis therapy under DOTS. Int
Immunopharmacol. 2009;8(6):845–51.
21. Prihoda ND, Arjanova OV, Yurchenko LV, Sokolenko NI, Vihrova LA,
Pylypchuk VS, et al. Open label trial of adjuvant immunotherapy with
Dzherelo, Svitanok and Lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected
patients receiving anti-tuberculosis therapy under DOT. J Med Plants Res.
2007;1:117–22.
22. Prihoda ND, Arjanova OV, Yurechenko LV, Sokolenko NI, Vihrova LA.
Adjuvant immunotherapy of extensively drug resistant tuberculosis (XDR-TB)
in Ukraine. Curr Res Tuberc. 2009;1(1):9–14.
23. Prihoda ND, Arjanova OV, Yurchenko LV, Sokolenko NI, Vihrova LA,
Pylypchuk VS, et al. Adjunct immunotherapy of tuberculosis in drug-
resistant TB and TB/HIV co-infected patients. Int J Biomed Pharm Sci. 2008;
2(1):59–64.
24. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YL, Frolov VM, Kutsyna GA.
Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from
adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin.
Cytokine. 2008;44(3):392–6. https://doi.org/10.1016/j.cyto.2008.10.009.
25. Sackett DL, Cook DJ. Can we learn anything from small trials? Ann NY Acad
Sci. 1993;703(1):25–32. https://doi.org/10.1111/j.1749-6632.1993.tb26331.x.
26. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the
size of an individual trial still matter? PLoS Med. 2008;5(1):0003–5.
27. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is
everything - large amounts of information are needed to overcome
random effects in estimating direction and magnitude of treatment effects.
Pain. 1998;78(3):209–16. https://doi.org/10.1016/S0304-3959(98)00140-7.
28. Faber J, Fonseca LM. How sample size influences research outcomes. Dental
Press J Orthod. 2014;19(4):27–9. https://doi.org/10.1590/2176-9451.19.4.027-
029.ebo.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kitenge et al. Systematic Reviews          (2021) 10:157 Page 11 of 11
